Quetiapine monotherapy for bipolar depression

Figures & data

Figure 1a Least-squares mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at each assessment of outpatients with bipolar I or II disorder who experienced a major depressive episode (BOLDER I).

Figure 1b Least-squares mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at each assessment of outpatients with bipolar I or II disorder who experienced a major depressive episode (BOLDER II).

Figure 2 Percentage improvement from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) individual items scores in outpatients with bipolar I or II disorder (data pooled from BOLDER I and BOLDER II studies; ITT, LOCF).

Figure 3 Least mean squares change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score in outpatients with bipolar I or II disorder (data pooled from BOLDER I and BOLDER II studies; ITT, LOCF).

Figure 4 Least mean squares change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score in outpatients with bipolar I or II disorder and rapid or non-rapid cycling (data pooled from BOLDER I and BOLDER II studies; ITT, LOCF).

Table 1 Most common adverse events associated with quetiapine treatment in outpatients with bipolar I or II disorder (≥5% patients; data pooled from BOLDER I and BOLDER II studies)

Adverse event (%)	Quetiapine 300 mg (n =350)	Quetiapine 600 mg (n =348)	Placebo (n =347)
Dry mouth	43.4	43.7	12.7
Sedation	30.9	29.9	8.1
Somnolence	28.6	27.0	6.6
Dizziness	15.4	19.5	6.9
Constipation	10.0	10.6	3.7
Lethargy	5.7	5.2	1.7
Weight increase	2.9	5.7	1.2